THINPREP PAP TEST
The ThinPrep® family is the leader in cervical cancer prevention, having to show very important first place records:
― It is the first FDA approved Liquid Based Cytology Test, which is significantly more efficient than the conventional test3*
― It is the first FDA approved test for detecting adenocarcinoma3
― It is the first FDA approved test using automated slide scanning Imaging System
― It is the first FDA approved test appropriate for HPV testing sample collection**
― Celebrating 20 years of ThinPrep® Pap Test
This year we proudly celebrate 20 years of ThinPrep® Pap Test.
When ThinPrep® Pap Test was approved and started being used in 1996, all Pap Tests were performed by the conventional method and the HPV Test was not even part of the algorithm in women’s cervical cancer prevention. Since then, there has been a significant reduction in cancer incidents in the USA1.
This, undoubtedly, was an important progress in prevention.
Today, more than 650 million ThinPrep® Pap Tests have been conducted and, at the same time, more that 6,000 ThinPrep®2 processors are used.
― An exclusive method of gynaecological testing in the biggest hospitals and diagnostic centers in Greece.
Since 2015, in cooperation with Group Generali, Thin Prep has become the exclusive method for conducting gynaecological testing, both for prevention and for diagnosis in the largest hospitals and diagnostic centers in Greece.
― Pap Test + HPV Test: the strategy for success in preventing cervical cancer
Today, the combination of Pap Test + HPV Test (co-testing) is considered to be the best strategy for detecting high-grade lesions in women between 30 and 65 years old, according to the most recent clinical studies5,6.
This means that only ONE sample collection, covers for a woman all prevention testing for cervical cancer
Recent Guidelines of the USA Obstetrics/ Gynaecologists Conference also advise the combination of Pap Test + HPV Test as the method of choice for women’s testing7.
* ThinPrep® Pap Test is significantly more effective than the conventional Pap Test in detecting low-grade squamous intraepithelial lesions (LSIL) and more serious lesions in various groups of women.
** Aptima HR HPV test, Aptima GT test, Cervista® HPV HR Test, the Cervista® HPV 16/18 Test, the Roche cobas® HPV Test and the Digene Hybrid Capture System HPV DNA test.
The information referred to for general information and informing the public and in any case can not replace a doctor or other suitably qualified health professional. The responsibility of the media carries by ENORASIS SA
1. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed April 28, 2016.
2. Hologic, Inc. Data on File.
3. ThinPrep 2000 System [package insert]. MAN-02060-002 Rev. 001. Marlborough, MA: Hologic, Inc.; 2011.
4. U.S. News & World Report. Best Hospitals for Adult Gynecology. http://health.usnews.com/best-hospitals/rankings/ gynecology. Published 2016. Accessed April 28, 2016.
5. Blatt, et al. Comparison of Cervical Cancer Screening Results Among 256,648 Women in Multiple Clinical Practices. Cancer Cytopathol. 2015;123(5):282-8. doi:10.1002/cncy.21544.
6. Zhao, et al. Clinical Performance of the Food and Drug Administration-Approved High-Risk HPV Test for the Detection of High-Grade Cervicovaginal Lesions [published online ahead of print January 15, 2016]. Cancer Cytopathol. doi:10.1002/cncy.21687.
7. ACOG. Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127:e1-20. doi:10.1097/AOG.0000000000001256.